Operating Segments (Tables)

9 Months Ended

Sep. 30, 2024

Operating Segments

Schedule of operating segments

	Three Months Ended
	September 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		—		130,440
Total	$	—	$	130,440
Income (loss) from Operations
Specialized BioTherapeutics	$	(834,654)	$	(705,753)
Public Health Solutions		(57,611)		(24,819)
Corporate		(972,971)		(1,048,484)
Total	$	(1,865,236)	$	(1,779,056)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	953	$	954
Public Health Solutions		158		159
Corporate		478		476
Total	$	1,589	$	1,589
Other (Expense) Income, Net
Specialized BioTherapeutics	$	1,409	$	1,683
Corporate		144,446		114,671
Total	$	145,855	$	116,354
Share-Based Compensation
Specialized BioTherapeutics	$	20,598	$	27,427
Public Health Solutions		618		994
Corporate		35,416		36,979
Total	$	56,632	$	65,400

	Nine Months Ended
	September 30,
	2024		2023
Revenues
Specialized BioTherapeutics	$	119,371	$	223,870
Public Health Solutions		—		370,677
Total	$	119,371	$	594,547
Income (loss) from Operations
Specialized BioTherapeutics	$	(1,978,464)	$	(2,227,430)
Public Health Solutions		(165,660)		(26,639)
Corporate		(3,582,878)		(3,306,000)
Total	$	(5,727,002)	$	(5,560,069)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,859	$	2,979
Public Health Solutions		476		496
Corporate		1,430		1,489
Total	$	4,765	$	4,964
Other (Expense) Income, Net
Specialized BioTherapeutics	$	(22,397)	$	17,696
Corporate		470,189		60,341
Total	$	447,792	$	78,037
Share-Based Compensation
Specialized BioTherapeutics	$	62,210	$	82,281
Public Health Solutions		1,823		2,982
Corporate		110,235		143,813
Total	$	174,268	$	229,076

	As of		As of
	September 30,		December 31,
	2024		2023
Identifiable Assets
Specialized BioTherapeutics	$	45,674	$	272,099
Public Health Solutions		2,387		3,976
Corporate		10,428,918		9,521,251
Total	$	10,476,979	$	9,797,326